The Rutgers Cancer Institute of New Jersey Experience.
While the potential benefit of precision medicine is substantial, research has shown that its implementation in the Latino population is limited. At the Rutgers Cancer Institute of New Jersey (RCINJ), during 2013–2017, 65.3% of new patient visits were non-Latino white patients and 8.9% were Latino. In a clinical trial evaluating the outcomes of patients who have had genomic testing on their tumors (N = 770), 71% were non-Latino white patients, while 11% were Latino. This ongoing trial consistently demonstrates that targeted therapy based on genomic profiling of tumors improves outcomes in cancer care and that Latinos are willing to participate in the clinical trial that involves genomic testing at a cancer center.